Tshwane:The Council for Scientific and Industrial Research (CSIR) has unveiled the FuturePHARMA facility, aiming to bridge the gap between scientific discoveries and the local pharmaceutical industry.

According to South African Government News Agency, the facility's launch highlighted South Africa's reliance on imported active pharmaceutical ingredients (APIs), with 98% of these APIs being sourced from abroad. This dependency makes the local pharmaceutical manufacturing sector vulnerable to external shocks and currency fluctuations. The FuturePHARMA initiative seeks to enhance the country's ability to translate early-stage research into scalable pharmaceutical products.

The first phase of the project focuses on developing translational capabilities to advance research into clinical testing and local manufacturing. The second phase will emphasize scaling these capabilities and strengthening the healthcare system to improve readiness for future health challenges.

Dr. Rachel Chikwamba, CSIR Group Executive for Advanced Chemistry and Life Sciences, explained that the facility would provide the necessary infrastructure, skills, and expertise to support the development of medicines, including both small-molecule drugs and biopharmaceuticals. The aim is to enable seamless progress from research concepts to full-scale manufacturing.

FuturePHARMA is designed as an open-access platform for researchers and entrepreneurs, offering access to infrastructure and expertise without requiring significant initial investments. This model is expected to foster a pipeline of new pharmaceutical businesses and develop a skilled workforce for the African pharmaceutical sector.

The South African Health Products Regulatory Authority (SAHPRA) views FuturePHARMA as crucial to bolstering regulatory and manufacturing ecosystems for local production. SAHPRA CEO Dr. Boitumelo Semete-Makokotlela emphasized the need for alignment between various sectors to support local manufacturing and ensure medicine access and health security.

The World Health Organisation (WHO) representative to South Africa, Dr. Shenaaz El-Halabi, praised FuturePHARMA's role in addressing the challenge of turning scientific discoveries into effective and affordable medicines. The facility supports Africa's goal of enhancing its health security through sustainable local production.

Looking forward, Chikwamba described FuturePHARMA as a 'sandbox' that will maintain active capabilities and ensure rapid response readiness for health emergencies. This setup will facilitate continuous production and workforce training, ensuring preparedness ahead of future crises.